GlassScriptPhysician profile
Shuchi Pandya
NPI 1669869822
$1,252.68
in general payments reported to CMS, 2019-2025
13 companies · $26.62 in 2025
The $26.62 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $73.36 · 2021: $113 · 2022: $201 · 2023: $288 · 2024: $159 · 2025: $26.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $333.25 | 2021-2024 | Arikayce |
| Astellas Pharma US INC | $263.97 | 2019-2022 | |
| Gilead Sciences, INC. | $185.81 | 2019-2023 | |
| Viiv Healthcare Company | $117.55 | 2019-2023 | Cabenuva, Dovato |
| Abbvie INC. | $103.20 | 2021-2024 | |
| Melinta Therapeutics, LLC | $62.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $61.72 | 2019-2024 | Dificid, Zerbaxa, Prevymis |
| Glaxosmithkline, LLC. | $26.62 | 2025 | Shingrix |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Genentech USA, INC. | $24.56 | 2019 | |
| Dynavax Technologies Corporation | $22.18 | 2021 | |
| Shionogi INC | $13.52 | 2020 | |
| Allergan, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuchi Pandya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.